ET501 / Expression Therap - LARVOL DELTA

Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with High-Risk Neuroblastoma (PRNewswire) - "Over two years, the award funds program activities intended to support an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA)....ET501 applies the company's ADEPT-STAR platform, which uses the company's LENTeT lentiviral delivery system to engineer γδ T cells that secrete a T-cell engager at the tumor site."

Financing • Neuroblastoma